Adrian Senderowicz Sells 27,000 Shares of Puma Biotechnology (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Adrian Senderowicz sold 27,000 shares of the company’s stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $7.20, for a total transaction of $194,400.00. Following the sale, the director owned 27,000 shares of the company’s stock, valued at $194,400. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Puma Biotechnology Stock Down 3.5%

PBYI stock traded down $0.26 during mid-day trading on Monday, reaching $7.07. 177,368 shares of the stock traded hands, compared to its average volume of 189,537. Puma Biotechnology, Inc. has a 52 week low of $3.03 and a 52 week high of $7.90. The business has a 50-day moving average of $7.23 and a two-hundred day moving average of $6.57. The firm has a market capitalization of $359.86 million, a PE ratio of 14.73 and a beta of 1.21.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.09. The company had revenue of $44.81 million during the quarter, compared to analysts’ expectations of $42.00 million. Puma Biotechnology had a net margin of 10.69% and a return on equity of 20.30%. On average, equities research analysts anticipate that Puma Biotechnology, Inc. will post 0.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its stake in shares of Puma Biotechnology by 244.5% during the first quarter. Royal Bank of Canada now owns 4,320 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 3,066 shares during the last quarter. Cerity Partners LLC bought a new stake in shares of Puma Biotechnology during the second quarter valued at approximately $36,000. BNP Paribas Financial Markets grew its stake in shares of Puma Biotechnology by 39.7% during the third quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 2,290 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Puma Biotechnology during the fourth quarter valued at approximately $49,000. Finally, State of Alaska Department of Revenue bought a new stake in shares of Puma Biotechnology during the fourth quarter valued at approximately $50,000. Institutional investors and hedge funds own 61.29% of the company’s stock.

Analyst Upgrades and Downgrades

PBYI has been the subject of a number of research analyst reports. Weiss Ratings lowered shares of Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Wall Street Zen lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 16th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock presently has a consensus rating of “Hold”.

About Puma Biotechnology

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.